

KEYWORD SUBJECT INDEX

Angiophysiology,

- Human myometrium: P-31.
- Pharmacotherapy: P-31.
- Renal arteries: P-31.
- Spermatic veins: P-31.
- Uterine arteries: P-31.
- Vasoconstriction: P-31.

Amifostine,

- Human endothelial cells: P-26.
- In vivo system: P-26.
- Radioprotectant: P-26.

Anesthesia: O-26.

Betatron: O-12, P-4, P-54.

Bile duct cancer:

- Curative resection: P-62.
- Intraluminal radiotherapy,
 - «Micro Selectron HDR» Iridium 192: P-61.
- Late-onset complication: P-62.
- Postoperative external radiation: P-62.
- Primary: P-60.

Bladder cancer,

- Bladder function: I-4.
- Bladder preservation: I-5.
- Chemotherapy: I-5.
 - Concomitant Cis Platinum: I-4.
- Conservative treatment: I-4.
- Electron: I-4.
- Iridium 192 brachytherapy: I-4.
- Pathologic findings in cystectomy: I-5.
- Preoperative external beam radiotherapy: I-5.

Brain tumors: P-37.

- Anaplastic oligodendroglioma: P-36.
- High grade glioma:
 - Grade III: O-7, P-36.
 - Glioblastoma (grade IV): O-7, P-36.
 - Haemorrhage: O-7.
 - Infections: O-7.
 - Malignant edema: O-7.
- Primary: O-7, P-36.
- Recurrent: O-7, P-36.

Breast cancer: P-77, P-82

Cancer cell lines,

- Biliary tract radioresistant,
 - Radiosensitization 5FU: P-25.
 - Cellular proliferation: P-25.
 - Duration of exposure: P-25.
 - Effect of timing: P-25.

Cervix cancer,

- Brachytherapy: O-18.
- Concomitant 5FU-CDDP: O-18.
- Contact radiotherapy: P-64.
- Flexible applicators: P-54.
- Iliac vessels: P-64.
- «MicroSelectron HDR» Ir- 192: P-64.
- «Microtron-M»: P-65.
- Neuritis: O-18.
- Ovarian function: P-65.
- Ovarian transposition: P-65.
- Parametrium: P-64.
- Preoperative external beam radiotherapy: O-18.
- Radical surgery: O-18.
- Rectitis: O-18.
- Vagina stump: P-64.

Colorectal cancer:

- Bladder fistula: P-72.
- 5FU: P-72.
- Hidronephrosis: P-72.
- Locally advanced,
 - HDR-Iridium-Afterloading: P-71.
- Radioimmunoguided intraoperative radiation,
 - CC49 antibody: O-20.
 - Electron beams: O-20.
 - High-dose rate brachytherapy: O-20.
 - Iodine 125 (I-125): O-20.
 - Radioimmunoguided surgery (RIGS): O-20.
 - Radiolabeled monoclonal antibodies: O-20.
- Recurrent,
 - Electron beams: P-70.
 - Enteric-urinary fistula: P-70.
 - HDR-Iridium-Afterloading: P-68, P-71.
 - Pelvic pain: P-70.
- Metastatic,
 - High-dose rate brachytherapy (IOHDR): P-68.
- Uretral rupture: P-72.

Complications,

- Abdominal infection: P-53.
- Anastomotic lake: P-53, P-71, P-72.
- Bladder fistula: P-70, P-71, P-72.

- Bleeding: P-53, P-57.
- Bronchopleuroesophageal fistula: P-44.
- Cerebral infections: O-7.
- Empyema: P-44.
- Enteric fistula: P-30, P-70.
- Hematemesis: P-30.
- Hemorrhage: O-7, P-44.
- Hemothorax: P-44.
- Hidronephrosis: P-72.
- Ileus: P-53.
- Intestinal occlusion: P-72.
- Lethal: P-42.
- Malignant edema: O-7.
- Mandible necrosis: P-40.
- Myelopathy: O-25.
- Neuropathy: O-2, O-18, O-22, O-23, P-6.
- Ocular: P-74.
- Orofistula: P-40, P-42.
- Pericarditis: O-11.
- Perineal wound: P-71, P-72.
- Pneumonia: P-44, P-53.
- Proctitis: O-18, P-6.
- Radiation pneumonitis: O-11.
- Recurrent urinary infections: P-74.
- Thromboembolism: P-44.
- Urethral: P-72, P-74.
- Vascular,
 - Aorto-jejunal fistula: P-30.
 - Endarteritis: P-30.
 - Hepatic artery: P-30.
 - Venous prosthesis: P-30.

Dosimetry:

- »Air docking system»: P-11.
- Beam blocking,
 - Depth of penetration: O-3.
- CT-based reconstruction,
 - Experimental irradiation in dogs: O-4.
 - Pre-planning: O-4.
 - 3-dimensional positions: O-4.
- Electron beam,
 - Monte Carlo modeling: P-14.
- NOVAC7: P-5, P-16, P-18.
 - Gaf-chromic films: P-15, P-38.
- Optical Stimulation Luminescence,
 - Phantom in vivo measurements: P-13.
 - Dose mapping on tumor bed: P-13.
- Pelvic cavity,
 - Dose-area histograms: P-21.
 - Film dosimetry: P-21.

- TLDs: P-21.
- Scanditronix p-Si electron diode,
 - Angular dependence: P-20.
- Software,
 - Preoperative CT or MR: P-3.
 - Surgery simulation: P-3.
- Thermoluminescent dosimetry (TLD): P-13, P-21.
- Timer error: P-83

Gastric cancer: P-59.

- Adjuvant IORT randomized trial: O-16.
- Betatron: P-54.
- Complications,
 - Abdominal infection: P-53.
 - Anastomotic leak: P-53.
 - Bleeding: P-53, P-57.
 - Ileus: P-53.
 - Pneumonia: P-53.
- Extended lymphadenectomy: O-17.
- Intra-aortalis cisplatin: P-55.
- Intravenous hypoxic radiosensitizer Sanazol: P-56.
- Limited lymph node dissection: O-17.
- Mimicking late recurrence: P-58.
- Neoadjuvant chemotherapy: P-57.
- Preoperative irradiation: P-53, P-58.
- Postoperative chemotherapy: O-17.
- Postoperative radiotherapy: O-17.
- Randomized trial: P-53.
- Resectable: P-53.
- Stage III: P-54, P-55.

Gold-grain implants,

- Uterine cervix carcinoma,
 - Non-central pelvic recurrences: P-80.

Head and neck cancers,

- Advanced: O-10.
- Electron beam: P-39.
 - Anatomical sites inaccessible for: P-40.
- High-dose rate brachytherapy (IOHDR): P-40.
- Intensified multi-modality treatment: O-9.
- Neck dissection: O-8.
- Oral cavity, complications,
 - Hematoma: P-42.
 - Hyperemia: P-42.
 - Lethal: P-42.
 - Orofistula: P-42.
 - Tissue edema: P-42.
- Oral cavity, small-sized betatron: P-41.
- Oropharyngeal: I-1.
- Paclitaxel: O-9.

- Palliative therapy: O-10.
- Platinol: O-9.
- Previously irradiated irresectable: P-39, P-40.
- Recurrent: O-10.

High dose (HDR) brachytherapy:

- Ewing's sarcoma: P-6
- Flab material: O-2, P-6.
- Fraccionated: O-2.
- Gynecological tumors: O-2.
- HDR 192- Iridium: P-6.
- Hemorrhage cystitis: P-6.
- Nerval dysfunction: P-6.
- Proctitis: P-6.
- Rectal cancer: O-2, O-20, P-68, P-71.
- Soft tissue sarcomas: O-2, P-6.
- Temporary pareses: O-2.
- Tumor recurrences: P-79.

Hipoxic cell sensitizer:

- KU-2285: P-22.
- Pancreatic cancer: P-22, P-23.
- Osteosarcoma: P-22.

Lung cancer,

- Complications,
 - Bronchial hemorrhage: P-44.
 - Bronchopleuroesophageal fistula: P-44.
 - Empyema: P-44.
 - Hemothorax: P-44.
 - Pneumonia: P-44.
 - Thromboembolism: P-44.
- Chemo-radiation: I-2.
- Neoadjuvant chemotherapy: I-2, P-45.
- Non small cell lung cancer: I-2, P-43.
- Pancoast: I-2.
- Small betatron: O-12.
- Stage III: I-2, O-12, P-44.

Melanoma:

- B16F10 melanoma cells: P-28.
- B16 melanoma liver metastases: P-27.
- Glutathione: P-27, P-28.
- Cyclophosphamide: P-27.
- Oxothiazolidine carboxylate (OTZ): P-27, P-28.
- Proliferation rate: P-28.
- Therapeutic index: P-27.

Mesothelioma:

- Chemotherapy: O-11.

- Mobetron: O-11.
- Pericarditis: O-11.
- Radiation pneumonitis: O-11.

Metastatic spinal tumors:

- Microtron: O-25.
- Myelopathy: O-25.
- Postoperative radiotherapy: O-25.

Microtron: P-10.

- »Microtron-M« without tubes: P-12, P-65.

Mobetron:

- Clinical use: P-7.
- Feasible: O-1.
- Mesothelioma: O-11.
- Quality assurance (QA): P-7.

NOVAC7: P-1, P-2, P-8.

- Bremsstrahlung photons: P-17.
- Dosimetric result: P-5.
- Dosimetry: P-15, P-16, P-18.
- Electron leakage: P-17.
- Isodose curves: P-9.
- Ocular and adnexial tumors: P-38.
- Radiation around: P-17.

Ocular Tumors: P-38.

Pancreatic cancer:

- Adjuvant radiation therapy: O-13, O-15.
- Intra-arterial chemotherapy: P-51.
- Concurrent chemoradiotherapy: P-51.
- Curative resection: O-14, O-15, P-47.
- 5FU: P-46, P-47.
- Hipoxic cell sensitizer: P-23.
- Human pancreatic cancer cells lines (SUIT-2, PANC-1, and MIA PcCa-2): P-23.
- Pain reduction: P-46, P-48.
- Pancreatectomy: P-50.
- Pancreatic resection: P- 48, P-52.
- Pancreatoduodenectomy: P-49.
- Preoperative radiotherapy: O-15, P-51, P-63.
- PR- 350: P-23.
- Quality of live: P-48.
- Radical surgery: O-13.
- Radiochemotherapy: P-46.
- Surgical resection: P-63.
- Survival 10-years: P-49.
- Unresectable recurrent tumor: P-49.

Pediatric tumors:

- Ewing's sarcoma: P-75.
- Neuroblastoma: P-75.
- Soft tissue malignancies,
 - Electron beams: P-73.
 - High-dose rate brachytherapy (IOHDR): P-74.
 - Impaired orbital growth: P-74.
 - Loss of visual acuity: P-74.
 - Nephrectomy: P-74.
 - Recurrent urinary infections: P-74.
 - Urethral stenosis: P-74.

Psychosomatics,

- Anthropology: P-35.
- Respiratory therapy: P-35.
- Somatic training: P-35.

Public Hospital: P-81.

Radiobiological equivalence:

- α/β ratio: P-19.
- Biologically equivalent doses: P-19.
- Microsoft Excel: P-19.

Radiogenic vesical motor reactions,

- Pharmacotherapy: P-34.

Radioimmunoguided intraoperative radiation therapy:
O-20.

Rectal cancer:

- Adjuvant chemotherapy: O-19.
- Concomitant chemotherapy: O-19.
- Interstitial brachytherapy: O-19.
- Locally advanced: O-21, P-67.
- Perioperative morbidity: P-66.
- Preoperative chemoradiation: P-67.
- Preoperative radiation therapy: P-66.
- Prognostic factors: P-66.
- Randomized study: O-21.
- Recurrent: O-19, O-21.
- Surgery alone: P-66.
- Tumor downstaging: P-67.

Rectum or Rectosigmoid:

- Preoperative radiotherapy: P-69.
- Primary inoperable cancer: P-69.
- Recurrent cancer: P-69.

Russia, IORT in:

- Experimental studies on rabbits and dogs: P-79.
- Kiev Research Roentgeno-Radiological and Oncological Institute: P-79.

Sarcomas,

- Central,
 - Head and neck: O-24.
 - Neoadjuvant and / or adjuvant chemotherapy: O-24.
 - Pelvic: O-24.
 - Retroperitoneum: O-23, O-24.
 - Neurologic pain: O-23.
 - Peripheral neuropathy: O-23.
 - Truncal: O-24.
- Extremity:
 - Adjuvant chemotherapy: O-22, P-76.
 - Amputations: O-22.
 - Neoadjuvant chemotherapy: O-22.
 - Neuropathy: O-22.
 - Surgical resection: P-76.
- Pediatric: P-73, P-74.

Tissue tolerance:

- Adult dogs and single large dose,
 - Duodenum: P-33.
 - Kidneys: P-33.
 - Large vessels: P-33.
 - Pancreas: P-33.
- Bone degeneration,
 - Single dose: P-32.
- Canine liver: O-6.
- 5 Beagles: O-6.
- Liver resections: O-6.
- Long term follow-up,
 - Late sequelae: O-5.
 - Tumor recurrence: O-5.
 - Functional outcome: O-5.
- Long term histopathological tissue effects: O-6.
- Pathological findings: P-33.
- Surgically manipulated: O-6.
- Toxicity: P-29.

Ultrastructural changes:

- Collagen fiber: P-24.
- Vascular structure: P-24.

INSTITUTIONS INDEX

AUSTRIA

- Institute f. Psychology, Dept. of Clinical Psychology, University Vienna: P-35.
- Institute of Radiotherapy and Radio-Oncology, Salzburg: P-11.

CHINA

- China-Japan Freindship Hospital, Beijing, Dept. of Radiation Oncology: P-33.
- General Hospital of PLA, Beijing, Dept. of Radiation Therapy: P-43, P-60.

FRANCE

- Centre Hospitalier U. Lyon-Sud (CHUS), Lyon: I-4, I-8, O-17, O-26.
- CRLC Val d'Aurelle, Montpellier: P-13.
Dept. of Radiotherapy: P-30.
Dept. of Surgery: P-30.
- Hospices Civils de Lyon, Lyon,
Dept. of Radiotherapy: O-18.
- University Hospital Bellevue, Saint-Etienne,
Cervico-facial Surgery: I-1
Otolaryngology: I-1.
Radiotherapy: I-1.
- University Montpellier II: P-13.

GERMANY

- Deutsches Krebsforschungszentrum, Heidelberg: O-4.
- Klinikum Grosahadeun, Ludwig-Maximilians University, Munich,
Dept. of Radiation Oncology: O-16.
Dept. of Surgery: O-16.
- Paraoelsus Clinic, Osnabrueck: O-7.
- Paulusklinik, Düren: O-10.
- Städtische Kliniken, Offenach: P-71.
- Universitätsklinikum Essen: P-57.

- University of Heidelberg, Heidelberg,
Dept. of Radiotherapy: O-4, P-21, P-46.
- University Hospital, Aachen,
Dept. of Radiation Therapy: O-10, P-26.
Dept. of Pathology: P-26.
ENT-Department: O-10.
- University of Muenster,
Dept. of Neurosurgery: O-7.
Dept. of Orthopedics: O-2, P-6.
Dept. of Radiation Oncology: O-2, O-7, O-16,
P-6, P-31, P-34.
Dept. Of Surgery: P-31.

ITALY

- Az. Osp. Bianchi-Melacrino-Morelli, Regio Calabria:
D.O. Fisica Sanitaria: P-5.
O.O. Radioterapia: P-5.
- Azienda Ospedaliera S. Filippo Neri, Roma: P-8, P-16, P-17, P-18.
- Azienda Ospedaliera S. Camillo-Forlanini, Roma: P-17.
- Hitesys S.p.A. Aprilia: P-9, P-15, P-16, P-38.
- S. Chiara Hospital, Trento,
Dept. of Radiotherapy: P-47, P-72.
Dept. of Surgery: P-47, P-72.
Dept. of Health Physics: P-72.
- Treviso,
Fisica Sanitaria OC: P-1, P-2.
Radioterapie OC: P-1, P-2.
- Università Cattolica del Sacro Cuore, Roma: P-38.
Inst. di Clinica Chirurgica: O-15, O-19, P-50, P-66.
Inst. di Fisica: P-15.
Inst. di Radiologia: O-15, O-19, P-50.
Inst. di Radioterapia: P-66.

JAPAN

- Kinki University,
Dept. of Radiology: P-51.
- Kochi Medical School, Nankoku,
Dept. of Radiology: P-32.
Dept. of Surgery: P-24, P-32.
- Kyoto University,

- Chest Dis Res. Institute: P-23.
- Dept. of Radiology: O-14, P-22, P-51.
- First Dept. of Surgery: O-14, P-22, P-51.
- Nihon University, Tokyo,
 - Dept. of Radiology: O-25.
- Pola Chemical Industrial Inc.: P-23.
- The Institute of Clinical Medicine, University of Tsukuba, Tsukuba: P-25.
 - Dept. of Gastroenterology: P-63.
 - Dept. of Radiology: P-63.
 - Dept. of Surgery: P-63.
- Tochigi Cancer Center,
 - Dept. of Radiotherapy: P-10.
- Tokyo Metropolitan Komagome Hospital,
 - Dept. of Orthopedic Surgery: O-25.
 - Dept. of Radiation Therapy: P-62.
 - Dept. of Radiology: O-25.
- Yamagata University, Yamagata,
 - Dept. of Surgery: P-48, P-49.

KOREA

- Korea University,
 - Dept. of Neurosurgery: P-37.

NORWAY

- The Norwegian Radium Hospital, Oslo: O-21.

RUSSIA

- Cancer Research Institute, Tomsk: O-12, P-4, P-41, P-42, P-44, P-54, P-55, P-56.
- Medical Radiological Research Center, Obninsk: P-53, P-58, P-79.
- P.A. Ghersten Oncological Research Institute, Moscow: P-12, P-65.
- Cancer Research Center, Moscow,
 - Dept. of Radiosurgery: P-61, P-64.

SPAIN

- Centro Oncológico Príncipe de Asturias, Madrid: P-81.

- Clinica Universitaria, Pamplona: I-2, O-5, O-22, O-24.
 - Dept. of Oncology: I-5, I-9.
- HGU Gregorio Marañón, Madrid:
 - Dept. of Experimental Medicine: P-3.
 - Dept. of General Surgery III: P-52, P-59.
 - Dept. de Oncología: P-3, P-52, P-59, P-67, P-75, P-76.
- San Francisco de Asis Hospital, Madrid,
 - Dept. of General Surgery: P-77.
 - Dept. of Neurosurgery: P-36.
 - Dept. of Radiation Oncology: P-29, P-36, P-45, P-77.
 - Dept. of Thoracic Surgery: P-45.
- School of Medicine, Basque Country University, Leioa, Vizcaya,
 - Dept. of Physical Medicine: P-27, P-28.
 - Dept. of Radiology: P-27, P-28.
 - Dept. of Surgery: P-27, P-28.
- Universitat de Barcelona, Barcelona,
 - Dept. of Radiotherapy and Nuclear Medicine: P-79.

THE NETHERLANDS

- Catharina Ziekenhuis, Eindhoven,
 - Dept. of Radiotherapy: P-69.
 - Dept. of Surgery: P-69.
- University Hospital Groningen,
 - Dept. of Surgical Oncology: O-6.

U.S.A.

- Harvard School of Public Health, Boston, MA: P-25.
- Intraop Medical, Inc., Santa Clara: P-7.
- Massachusetts General Hospital: P-83
- Mayo Clinic, Rochester, NM: O-23, P-20.
- Medical College of Ohio, Toledo, OH,
 - Dept. of Medicine: O-13.
 - Dept. of Radiation Therapy: O-3, O-13, P-14, P-82.
 - Dept. of Surgery: O-13, P-82.
- MD. Anderson Cancer Centre, Houston, Texas,
 - Dept. Radiation Oncology: P-80.

KEYWORDS/TOPIC INDEX

- Ohio State University, Columbus, OH: O-9, P-68.
Arthur G. James Cancer Hospital & Research
Institute: O-9, O-20, P-39, P-70, P-73, P-74.
Division of Otolaryngology: P-39, P-40.
Division of Surgical Oncology: O-20, P-
70.
Division of Radiation Oncology: O-20,
P-39, P-40, P-70, P-19.
Children's Hospital: - P-73, P-74.
- University of California, San Francisco: P-7.
Dept. of Medicine: O-11.
Dept. of Otolaryngology: O-8.
Dept. of Radiation Oncology: O-1, O-8, O-11.
Dept. of Surgery: O-1, O-11.